133 related articles for article (PubMed ID: 10561181)
1. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors.
Baranzelli MC; Kramar A; Bouffet E; Quintana E; Rubie H; Edan C; Patte C
J Clin Oncol; 1999 Apr; 17(4):1212. PubMed ID: 10561181
[TBL] [Abstract][Full Text] [Related]
2. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
[TBL] [Abstract][Full Text] [Related]
3. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
4. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
5. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
de Wit R; Collette L; Sylvester R; de Mulder PH; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Stoter G
Br J Cancer; 1998 Nov; 78(10):1350-5. PubMed ID: 9823978
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
7. Non-seminomatous ovarian germ cell tumours in children.
Baranzelli MC; Bouffet E; Quintana E; Portas M; Thyss A; Patte C
Eur J Cancer; 2000 Feb; 36(3):376-83. PubMed ID: 10708940
[TBL] [Abstract][Full Text] [Related]
8. Malignant retroperitoneal and abdominal germ cell tumors: an intergroup study.
Billmire D; Vinocur C; Rescorla F; Colombani P; Cushing B; Hawkins E; Davis M; London WB; Lauer S; Giller R;
J Pediatr Surg; 2003 Mar; 38(3):315-8; discussion 315-8. PubMed ID: 12632341
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.
Saxman SB; Finch D; Gonin R; Einhorn LH
J Clin Oncol; 1998 Feb; 16(2):702-6. PubMed ID: 9469360
[TBL] [Abstract][Full Text] [Related]
10. Malignant sacrococcygeal germ cell tumors in children: a 30-year experience from a single institution.
Büyükpamukçu M; Varan A; Küpeli S; Ekinci S; Yalcin S; Kale G; Yalçin B; Kutluk T; Akyüz C
Tumori; 2013; 99(1):51-6. PubMed ID: 23549000
[TBL] [Abstract][Full Text] [Related]
11. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
12. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
13. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96.
Schneider DT; Calaminus G; Reinhard H; Gutjahr P; Kremens B; Harms D; Göbel U
J Clin Oncol; 2000 Feb; 18(4):832-9. PubMed ID: 10673525
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
15. AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89.
Calaminus G; Bamberg M; Harms D; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
Neuropediatrics; 2005 Apr; 36(2):71-7. PubMed ID: 15822019
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.
Calaminus G; Schneider DT; Bökkerink JP; Gadner H; Harms D; Willers R; Göbel U
J Clin Oncol; 2003 Mar; 21(5):781-6. PubMed ID: 12610174
[TBL] [Abstract][Full Text] [Related]
17. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
Fresneau B; Orbach D; Faure-Conter C; Sudour-Bonnange H; Vérité C; Gandemer V; Pasquet M; Fasola S; Rome A; Raimbault S; Martelli H; Frappaz D; Le Teuff G; Patte C
Eur J Cancer; 2018 May; 95():11-19. PubMed ID: 29604495
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
19. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Fizazi K; Tjulandin S; Salvioni R; Germà-Lluch JR; Bouzy J; Ragan D; Bokemeyer C; Gerl A; Fléchon A; de Bono JS; Stenning S; Horwich A; Pont J; Albers P; De Giorgi U; Bower M; Bulanov A; Pizzocaro G; Aparicio J; Nichols CR; Théodore C; Hartmann JT; Schmoll HJ; Kaye SB; Culine S; Droz JP; Mahé C
J Clin Oncol; 2001 May; 19(10):2647-57. PubMed ID: 11352956
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
